KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBIT Margin (2016 - 2026)

Neogenomics filings provide 17 years of EBIT Margin readings, the most recent being 9.77% for Q1 2026.

  • On a quarterly basis, EBIT Margin rose 679.0% to 9.77% in Q1 2026 year-over-year; TTM through Mar 2026 was 14.25%, a 96.0% decrease, with the full-year FY2025 number at 15.93%, down 199.0% from a year prior.
  • EBIT Margin hit 9.77% in Q1 2026 for Neogenomics, down from 7.05% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 7.05% in Q4 2025 to a low of 44.4% in Q1 2022.
  • Median EBIT Margin over the past 5 years was 16.56% (2025), compared with a mean of 19.4%.
  • Biggest five-year swings in EBIT Margin: plummeted -3133bps in 2022 and later skyrocketed 1884bps in 2023.
  • Neogenomics' EBIT Margin stood at 19.02% in 2022, then soared by 37bps to 11.94% in 2023, then grew by 10bps to 10.7% in 2024, then surged by 34bps to 7.05% in 2025, then plummeted by -39bps to 9.77% in 2026.
  • The last three reported values for EBIT Margin were 9.77% (Q1 2026), 7.05% (Q4 2025), and 14.38% (Q3 2025) per Business Quant data.